Bellecapital International Ltd. held its stake in Sanofi (NYSE:SNY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,340 shares of the company’s stock at the end of the second quarter. Bellecapital International Ltd.’s holdings in Sanofi were worth $352,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the stock. Pennsylvania Trust Co boosted its stake in Sanofi by 0.4% in the second quarter. Pennsylvania Trust Co now owns 8,314 shares of the company’s stock worth $402,000 after buying an additional 37 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Sanofi by 0.7% in the second quarter. Rehmann Capital Advisory Group now owns 7,235 shares of the company’s stock worth $347,000 after buying an additional 47 shares in the last quarter. Weik Investment Services Inc. boosted its stake in Sanofi by 0.9% in the first quarter. Weik Investment Services Inc. now owns 5,895 shares of the company’s stock worth $267,000 after buying an additional 50 shares in the last quarter. Financial Advisors Network Inc. boosted its stake in Sanofi by 1.0% in the first quarter. Financial Advisors Network Inc. now owns 8,282 shares of the company’s stock worth $409,000 after buying an additional 84 shares in the last quarter. Finally, First City Capital Management Inc. boosted its stake in Sanofi by 0.3% in the first quarter. First City Capital Management Inc. now owns 38,289 shares of the company’s stock worth $1,733,000 after buying an additional 100 shares in the last quarter. 9.96% of the stock is owned by hedge funds and other institutional investors.
Shares of Sanofi (NYSE:SNY) traded up 0.23% on Tuesday, reaching $48.08. The company’s stock had a trading volume of 493,812 shares. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company has a market cap of $120.75 billion, a PE ratio of 11.54 and a beta of 0.88. The firm has a 50 day moving average of $48.11 and a 200 day moving average of $45.82.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. The firm’s revenue for the quarter was down 2.3% compared to the same quarter last year. Analysts predict that Sanofi will post $3.23 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Bellecapital International Ltd. Has $352,000 Position in Sanofi (NYSE:SNY)” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://stocknewstimes.com/2017/08/08/bellecapital-international-ltd-has-352000-position-in-sanofi-sa-nysesny-updated.html.
A number of equities research analysts recently weighed in on the company. BidaskClub cut Sanofi from a “buy” rating to a “hold” rating in a report on Friday, June 9th. J P Morgan Chase & Co raised Sanofi from an “underperform” rating to a “neutral” rating in a report on Tuesday, April 11th. Argus raised their price target on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Zacks Investment Research raised Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price target for the company in a report on Friday, June 2nd. Finally, Berenberg Bank cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.75.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
